Study directory

Schizophrenia studies

Compare studies and check their requirements with the research team.

Back to overview
More filters: keywords, city, remote
4306studies shown
Showing 3,421-3,432 of 4,306
Drug study icon
TerminatedEUCTR 2007-001097-90

A one-year multinational, multi-centre, randomised, double-blind, parallel-group, fixed-dose, bifeprunox study combining a 12 week placebo-controlled, quetiapine-referenced phase with a 12-month qu...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Bulgaria
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugA study involving a medication or substance.
Countries
Bulgaria, Greece
Sponsor
H. Lundbeck A/S
Condition
Schizophrenia
Drug study icon
CompletedEUCTR 2009-012567-33

A Phase 2, 6-Week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Oral OPC-34712 Once Daily and Aripiprazole Once Daily for Tr...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Bulgaria
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug
Countries
Bulgaria, Slovakia
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
Schizophrenia
Drug study icon
SuspendedEUCTR 2014-004878-42

A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of MIN-101 in Patients With Negative Symptoms of Schiz...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Bulgaria
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug
Countries
Bulgaria, Estonia, Latvia, ...
Sponsor
Minerva Neurosciences, Inc.
Condition
Schizophrenia
Drug study icon
CompletedEUCTR 2008-003984-38

A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE COMPARATOR CONTROLLED CLINICAL TRIAL TO STUDY THE EFFICACY AND SAFETY OF TWO DOSES OF LURASIDONE IN ACUTELY PSYCHOTIC SUBJECTS WITH SCHIZOPHR...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Romania
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug
Countries
Romania
Sponsor
Dainippon Sumitomo Pharma America Ltd
Condition
Schizophrenia
Drug study icon
CompletedEUCTR 2011-005766-38

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults with Sc...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Poland
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug
Countries
Poland, Romania
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
Schizophrenia
Drug study icon
TerminatedEUCTR 2017-002369-23

A phase II randomised, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of orally administered BI 409306 during a 28-week treatment period as adjunctive the...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Spain
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug
Countries
Spain
Sponsor
Boehringer Ingelheim
Condition
Schizophrenia
Drug study icon
CompletedEUCTR 2016-000285-28

A phase II randomised, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of 4 oral doses of BI 425809 once daily over 12 week treatment period in patient...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Austria
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug
Countries
Austria, Germany, Italy, ...
Sponsor
Boehringer Ingelheim Pharma GmbH & Co. KG
Condition
Schizophrenia
Drug study icon
CompletedEUCTR 2013-005015-28

A phase II randomised, double-blinded, placebo-controlled study to evaluate the efficacy, safety, and tolerability of four orally administrated doses of BI 409306 during a 12-week treatment perio...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Germany
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug
Countries
Germany
Sponsor
Boehringer Ingelheim Pharma GmbH & Co. KG
Condition
Schizophrenia
Drug study icon
CompletedEUCTR 2010-021984-33

A phase II/III, multi-center, randomized, 4-week, double-blind, parallel group, placebo and active-controlled trial of the safety and efficacy of RO4917838 vs. placebo in patients with an acute exa...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Slovakia
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug
Countries
Slovakia
Sponsor
F. Hoffmann-La Roche Ltd
Condition
Schizophrenia
Drug study icon
CompletedEUCTR 2020-003760-11

A phase III randomized, double-blind, placebo-controlled parallel group trial to examine the efficacy and safety of Iclepertin (BI 425809) once daily over 26 week treatment period in patients with ...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Germany
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug
Countries
Germany, Italy, Norway, ...
Sponsor
Boehringer Ingelheim Pharma GmbH & Co. KG
Condition
Schizophrenia
Drug study icon
CompletedEUCTR 2020-003726-23

A phase III randomized, double-blind, placebo-controlled parallel group trial to examine the efficacy and safety of iclepertin once daily over 26 week treatment period in patients with schizophreni...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Austria
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug
Countries
Belgium, Austria, Bulgaria, ...
Sponsor
Boehringer Ingelheim Pharma GmbH & Co. KG
Condition
Schizophrenia
Drug study icon
CompletedEUCTR 2020-003744-84

A phase III randomized, double-blind, placebo-controlled, parallel group trial to examine the efficacy and safety of Iclepertin once daily over 26 week treatment period in patients with schizophren...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Croatia
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug
Countries
France, Croatia, Hungary, ...
Sponsor
Boehringer Ingelheim RCV GmbH & Co KG
Condition
Schizophrenia
Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.